Research Articles from Managed Care

Michael Toscani, PharmD; Marc Riedl, MD, MS
With the advent of new disease-specific agents, some patients with HAE may find relief from its enormous physical and psychological toll
Anand A. Dalal, PhD; Sean D. Candrilli, PhD; Keith L. Davis, MA
The comparison found that maintenance therapy with fluticasone propionate-salmeterol combination was associated with a 14% reduction in risk of severe exacerbation, less health care utilization, and 25% lower COPD-related medical costs
Girishanthy Krishnarajah, MPH, MBA/MS; Monali Bhosle, PhD; Richard Chapman, PhD
A comparison of health care costs in patients with diabetes who do not initially respond to oral therapy suggests that it might be appropriate and clinically beneficial for providers to consider adding another oral agent, rather than up-titrating the current medication, particularly beyond intermediate dose levels
Richard C. Weiss, BS, MS; Derek van Amerongen MD, MS; Gary Bazalo, BS, MS, MBA; Mark Aagren, MS; Jonathan R. Bouchard, MS, RPh
Mary V. Mason MD, MBA, FACP; Amy Poole-Yaeger MD, FAAP; Brad Lucas MD, MBA, FACOG; Cathie R. Krueger, RN, BSN; Tamim Ahmed, Ph.D, MBA; Ian Duncan, FSA, FIA, FCIA, MAAA

Low-birth-weight outcome was reduced when women participated in a managed maternity program, compared with nonparticipants

Amy K. O'Sullivan, PhD; Jane Sullivan, MPH; Keiko Higuchi, MPH; A. Bruce Montgomery, MD
John W. Hales, MA, PhD; Stephen George, PharmD, MS, RPh
As Part D enrollees approach their coverage limits, their decisions are significantly affected through the doughnut hole period
James W. Davis, PhD; Ronald Y. Fujimoto, DO; Henry Chan, BS; Deborah T. Juarez, Sc.D
A straightforward method of identifying potentially non-urgent ED visits from administrative data can be employed to calculate population-based rates, which might be applied in the development of managed care programs
Teresa B. Gibson, PhD; Yonghua Jing, PhD; Edward Kim, MD, MBA; Erin Bagalman, MSW; Sara Wang, PhD
Mark A. Malesker, PharmD; Daniel E. Hilleman, PharmD
The use of a single-pill combination of amlodipine/valsartan resulted in higher acquisition costs but fewer clinic visits, laboratory tests, and electrocardiograms — and therefore lower gross costs — compared with the use of individual drug components